Retrospective, multicentre study highlighting the value of Erivedge® maintenance therapy in aBCC

Analysis taken from the 68/227 (30%) patients treated with Erivedge®, that have achieved a cCR1* dermato-oncology units in Italy1 (39-100) median age1 Analyse the impact of Erivedge® maintenance therapy after cCR on disease-related outcomes, specifically, on DFS

Main outcomes at median follow-up of 42.5 months (range 0–91)1

Correlation between DFS and treatment duration

DFS was longer when Erivedge® was maintained for >2 months after cCR (mDFS > 2 months: 470 days vs. mDFS ≤ 2 months: 175 days, p = .01)

The results of the study suggest that more days on Erivedge® treatment (TTD) and longer maintenance therapy after cCR (DTS) directly correlate to better DFS in patients with laBCC and mBCC

Click here to access the full publication

Please see full prescribing information for additional important safety information

Advanced BCC = locally advanced BCC (laBCC) + metastatic BCC (mBCC). *65 patients (96%) had laBCC and 3 patients (4%) had mBCC. BCC, basal cell carcinoma; cCR, clinical complete response; DFS, disease-free survival; mDFS, median disease-free survival; DTCR, days to cCR; DTS, days to Erivedge® stop after cCR; HHI, Hedgehog inhibitor; TTD, total treatment days. 1. Alfieri S, et al. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? Oncologist. 2024 May 3;29(5):e699-e707.

M-XX-00018375